Exploring epidemiological risk factors for cerebral amyloid angiopathy: Considerations for monoclonal antibody therapy in people with Alzheimer's disease
ADNC were significantly positively associated with the risk of CAA. The ADNC-CAA association was generally stronger among females, smokers, people with a history of stroke/memory complaints, APOE-ε4 carriers, and those without diabetes or heart conditions. Longitudinally, higher CAA risk was observed among males, older individuals, smokers, people with diabetes/heart conditions/lower MMSE scores, and APOE-ε4 carriers compared to their reference groups.
Authors
- Sanka Amadoru (ORCID: https://orcid.org/0000-0002-0522-6143)
- Paul A Yates (ORCID: https://orcid.org/0000-0001-9317-0145)
- Colin Louis Masters (ORCID: https://orcid.org/0000-0003-3072-7940)
- Liang Jin (ORCID: https://orcid.org/0000-0003-1695-3300)
- Andrew Huynh (ORCID: https://orcid.org/0000-0003-1921-858X)
- Yijun Pan (ORCID: https://orcid.org/0000-0002-1442-3333)
- Scott Wrigley (ORCID: https://orcid.org/0000-0003-0608-1414)
- Benjamin Goudey (ORCID: https://orcid.org/0000-0002-2318-985X)
- Yihan Wang (ORCID: https://orcid.org/0000-0002-5353-6250)
- Liwei Ma (ORCID: https://orcid.org/0000-0002-7867-8060)
Institutions
- The University of Melbourne (AU)
- Florey Institute of Neuroscience and Mental Health (AU)
- Austin Health (AU)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/alz.14602
- Citations
- 4
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.66
Funders
- Alzheimer's Association
- National Health and Medical Research Council